» Articles » PMID: 20233273

Diminished Cardiac Fibrosis in Heart Failure is Associated with Altered Ventricular Arrhythmia Phenotype

Overview
Date 2010 Mar 18
PMID 20233273
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: We sought to define the role of interstitial fibrosis in the proarrhythmic phenotype of failing ventricular myocardium.

Background: Multiple cellular events that occur during pathological remodeling of the failing ventricle are implicated in the genesis of ventricular tachycardia (VT), including interstitial fibrosis. Recent studies suggest that ventricular fibrosis is reversible, and current anti-remodeling therapies attenuate ventricular fibrosis. However, the role of interstitial fibrosis in the proarrhythmic phenotype of failing ventricular myocardium is currently not well defined.

Methods: Class II histone deacetylases (HDACs) have been implicated in promoting collagen biosynthesis. As these enzymes are inhibited by protein kinase D1 (PKD1), we studied mice with cardiomyocyte-specific transgenic over-expression of a constitutively active mutant of PKD1 (caPKD). caPKD mice were compared with animals in which cardiomyopathy was induced by severe thoracic aortic banding (sTAB). Hearts were analyzed by echocardiographic and electrocardiographic means. Interstitial fibrosis was assessed by histology and quantified biochemically. Ventricular arrhythmias were induced by closed-chest, intracardiac pacing.

Results: Similar degrees of hypertrophic growth, systolic dysfunction and mortality were observed in the two models. In sTAB mice, robust ventricular fibrosis was readily detected, but myocardial collagen content was significantly reduced in caPKD mice. As expected, VT was readily inducible by programmed stimulation in sTAB mice and VT was less inducible in caPKD mice. Surprisingly, episodes of VT manifested longer cycle lengths and longer duration in caPKD mice.

Conclusion: Attenuated ventricular fibrosis is associated with reduced VT inducibility, increased VT duration, and significantly longer arrhythmia cycle length.

Citing Articles

Harnessing stem cell and lineage reprogramming technology to treat cardiac fibrosis.

Zeng N, Tang W, Wu Y, Fan H, Xie S, Cao N Cell Regen. 2023; 12(1):39.

PMID: 38072904 PMC: 10710977. DOI: 10.1186/s13619-023-00182-7.


Bariatric surgery for diabetic comorbidities: A focus on hepatic, cardiac and renal fibrosis.

Ding H, Zhang Y, Ma X, Zhang Z, Xu Q, Liu C Front Pharmacol. 2022; 13:1016635.

PMID: 36339532 PMC: 9634081. DOI: 10.3389/fphar.2022.1016635.


Protective effects of Dapagliflozin on the vulnerability of ventricular arrhythmia in rats with pulmonary artery hypertension induced by monocrotaline.

Qin T, Kong B, Dai C, Xiao Z, Fang J, Shuai W Bioengineered. 2022; 13(2):2697-2709.

PMID: 35042435 PMC: 8974039. DOI: 10.1080/21655979.2021.2017652.


Aggressive beta-blocker titration in stabilized acute heart failure patients with low left ventricular ejection fraction.

Waranugraha Y, Rohman M, Setiawan D, Aziz I J Taibah Univ Med Sci. 2021; 16(4):582-590.

PMID: 34408616 PMC: 8348274. DOI: 10.1016/j.jtumed.2021.02.012.


Kanglexin protects against cardiac fibrosis and dysfunction in mice by TGF-β1/ERK1/2 noncanonical pathway.

Liu X, Han W, An N, Cao N, Wu T, Yang S Front Pharmacol. 2021; 11:572637.

PMID: 33519438 PMC: 7840489. DOI: 10.3389/fphar.2020.572637.


References
1.
Hill J, Karimi M, Kutschke W, Davisson R, Zimmerman K, Wang Z . Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation. 2000; 101(24):2863-9. DOI: 10.1161/01.cir.101.24.2863. View

2.
Lea W, Kwak E, Luther J, Fowler S, Wang Z, Ma J . Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 2009; 75(9):936-44. PMC: 2770712. DOI: 10.1038/ki.2009.9. View

3.
Petrov V, Fagard R, Lijnen P . Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension. 2002; 39(2):258-63. DOI: 10.1161/hy0202.103268. View

4.
Hill J, Rothermel B, Yoo K, Cabuay B, Demetroulis E, Weiss R . Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. J Biol Chem. 2002; 277(12):10251-5. DOI: 10.1074/jbc.M110722200. View

5.
Manabe I, Shindo T, Nagai R . Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res. 2002; 91(12):1103-13. DOI: 10.1161/01.res.0000046452.67724.b8. View